Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — FY2023 Earnings Presentation
12 slides from Tarsus Pharmaceuticals's earnings presentation, Feb 27, 2024
Slide 1: Fourth Quarter and Full-Year 2023 Financial Results Conference Call
Tarsus Pharmaceuticals Fourth Quarter and Full-Year 2023 Financial Results Conference Call February 27, 2024
Slide 2: Today's Speakers
Today’s Speakers Bobak Azamian, Aziz Mottiwala Sesha Neervannan, Jeff Farrow M.D., Ph.D. Ph.D. Chief Commercial Chief Financial Officer Chief Executive Officer Chief Operating Officer and Chief Strategy Officer and Chairman Officer 2
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations about future events that we believe
Slide 4: A Category-Creating Approach to Delivering Blockbuster Medicines and Serving Millions of Patients
A Category-Creating Approach to Delivering Blockbuster Medicines and Serving Millions of Patients XDEMVY® A ROBUST PIPELINE A GROUND-BREAKING LAUNCH WITH MULTIPLE 2024 CATALYSTS The first and only FDA-approved therapy for “Pipeline in a product” with multiple Demodex blepharitis category-creating pr
Slide 5: Demodex Blepharitis is a Potential $1B+ Opportunity
Demodex Blepharitis is a Potential $1B+ Opportunity GOAL 1.5M 1.2M 2.2M 2.3M >7M Patients with Demodex Proactively blepharitis (DB) Dry Eye Rx patients Cataract patients Contact lens seeking treatment with DB1,3,4,5 with DB1,3,6 patients with DB1,3,7 for complementary Already diagnosed eye condition
Slide 6: XDEMVY: Setting a New Standard for Product Launches
XDEMVY: Setting a New Standard for Product Launches Industry-Leading Team High-Impact Disease Education Clear Value Proposition • 85 territory leaders targeting • Action-oriented, visually • Strong traction with payers 15K ECPs covering >80% of focused physician and patient • Unique distribution mod
Slide 7: Ongoing Waves of ECP Adoption
Ongoing Waves of ECP Adoption U T I L I Z AT I O N A C R O S S S E G M E N T S Early Adopters Eager Treaters New to DB (Diagnosing and treating patients (Ready for an FDA-approved solution; (Beginning to diagnose, recognizing on Day 1) ramping TRx alongside patient successes) prevalence and acting)
Slide 8: XDEMVY: Delivering Strong Results
XDEMVY: Delivering Strong Results ~6,000 ECPs started patients on XDEMVY1 >50% repeat prescribers1,2 >17,400 bottles dispensed to patients3 Better than expected 58% GTN discount3 Secured major commercial payer win: >19M covered lives4 $14.7 Million FY 2023 Net Product Sales 8 1. As of February 23, 2
Slide 9: A Category-Creating Pipeline With Near-Term Catalysts
A Category-Creating Pipeline With Near-Term Catalysts Tarsus Product Portfolio Product Upcoming Indication Formulation Preclinical Phase 1 Phase 2 Phase 3 Marketed Candidate Catalyst XDEMVY Demodex blepharitis (US) Eye drop TP-03 Demodex blepharitis (EU) Eye drop Evaluating preservative-free formula
Slide 10: TP-04: Statistically Significant Improvements in Inflammatory Lesions and IGA Score Compared to Placebo
Galatea Phase 2a Trial for the Treatment of Papulopustular Rosacea TP-04: Statistically Significant Improvements in Inflammatory Lesions and IGA Score Compared to Placebo Change from Baseline in Inflammatory Lesion Count Change from Baseline in IGA Score (Mean +/- SE) (Mean +/- SE) 10 0 Change from
Slide 11: Full Year 2023 Financial Results
Full Year 2023 Financial Results $14.7 million in net 58% gross-to-net discount product sales Better than anticipated In first 4 months of launch non-contracted coverage 17,400 XDEMVY bottles $227.4 million in cash dispensed to patients Strong foundation enables continued Steady week-over-week growt
Slide 12: Closing Remarks and Q&A
Closing Remarks and Q&A Dp Tarsus
Tarsus Pharmaceuticals — FY2023 Earnings Presentation on 6ix